The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer(The Alfred Hospital), Christine Chen(University Health Network), Jennifer Gauvin(Research Triangle Park Foundation), Joanna Opalinska(GlaxoSmithKline (United States)), Rakesh Kumar(The University of Texas MD Anderson Cancer Center), Shannon R. Morris(Research Triangle Park Foundation), Simon J. Harrison(Peter MacCallum Cancer Centre), Deborah A. Smith(Research Triangle Park Foundation), Sung‐Soo Yoon(Seoul National University Hospital), Richard A. Brigandi(GlaxoSmithKline (United States))
Cited by 140
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719